| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-11-04 | Actinium Pharmaceuticals (USA - NY) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-11-04 | Novo Nordisk (Denmark) | new insulin filling facility in Denmark | diabetes, obesity | construction of a production plant |
Metabolic diseases | Construction of a production plant |
| 2015-11-04 | Spark Therapeutics (USA - PA) | opening of new premises |
Rare diseases - Genetic diseases | Opening of new premises | ||
| 2015-11-04 | Arsanis (USA - MA) | nomination |
Infectious diseases | Nomination | ||
| 2015-11-04 | Allergan (Ireland) Mimetogen Pharmaceuticals (Canada) | tavilermide (MIM-D3) Topical Dry Eye | dry eye disease | licensing |
Ophtalmological diseases | Licensing agreement |
| 2015-11-03 | Novo Nordisk (Denmark) University of Washington (USA - WA) | diabetes | R&D |
Metabolic diseases | R&D agreement | |
| 2015-11-03 | BMS (USA - NY) Johns Hopkins Kimmel Cancer Center (USA - MD) | R&D collaboration |
Cancer - Oncology | R&D agreement | ||
| 2015-11-03 | Sanofi (France) BioNTech (Germany) | up to five cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs). | R&D licensing |
Cancer - Oncology | R&D agreement | |
| 2015-11-03 | Faron Pharmaceuticals (Finland) Selexis (Switzerland) | Clevegen® | development production manufacturing |
Cancer - Oncology - Technology - Services | Development agreement | |
| 2015-11-03 | Moberg Pharma (Sweden) Colep (Portugal) | MOB-015 (topical formulation of terbinafine) | onychomycosis | development |
Infectious diseases | Development agreement |
| 2015-11-02 | Juno Therapeutics (USA - WA) | nomination |
Nomination | |||
| 2015-11-02 | Merck KGaA (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-11-02 | Merck KGaA (Germany) Selvita (Poland) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2015-10-30 | Galena Biopharma (USA - OR) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-10-29 | Medicago (Canada) Department of Health and Human Services (HHS) (USA) | anti-Ebola virus monoclonal antibodies | Ebola fever | production manufacturing |
Infectious diseases | Production agreement |
| 2015-10-29 | Ultragenyx Pharmaceutical (USA - CA) Arcturus Therapeutics (USA - CA) | messenger RNA (mRNA) therapeutics using UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery platform | R&D licensing |
Rare diseases | R&D agreement | |
| 2015-10-29 | Pfizer (USA - NY) GSK (UK) | portable, continuous, miniature and modular (PCMM) oral solid dose development and manufacturing units | collaboration production manufacturing |
Technology - Services | Collaboration agreement | |
| 2015-10-29 | Medicago (Canada) Public Health Agency of Canada (PHAC) | antibodies against the Sudan strain of the Ebola virus | Ebola fever | services contract |
Infectious diseases | Services contract |
| 2015-10-29 | Domainex (UK) | opening of new premises |
Technology - Services | Opening of new premises | ||
| 2015-10-28 | Oxford Biomedica (UK) GSK (UK) | LentiVector® platform technology patents | licensing |
Rare diseases - Genetic diseases | Exercise of an option agreement |
